Glucotrack soars on completion of first human clinical study of continuous blood glucose monitor
Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...
Glucotrack sets terms for $3 million public stock offering
RUTHERFORD, NJ - Glucotrack, Inc. (NASDAQ:GCTK), a developer of medical technologies for diabetes care, has announced the pricing of its public offering at $1.15 per share, aiming to raise ...
Yahoo Finance3d
GlucoTrack, Inc. (GCTK)
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...
Glucotrack, Inc. Announces 1-for-20 Reverse Stock Split
Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...